Kyverna Therapeutics (NASDAQ:KYTX) Issues Quarterly Earnings Results

Kyverna Therapeutics (NASDAQ:KYTX) posted its quarterly earnings results on Tuesday. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09, FiscalAI reports.

Kyverna Therapeutics Price Performance

Shares of KYTX stock traded down $0.11 during mid-day trading on Tuesday, hitting $10.23. 612,894 shares of the stock were exchanged, compared to its average volume of 861,134. The firm has a fifty day moving average of $8.89 and a 200 day moving average of $8.30. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.11. Kyverna Therapeutics has a 52-week low of $2.06 and a 52-week high of $13.67. The company has a market cap of $619.22 million, a PE ratio of -2.80 and a beta of 2.05.

Analyst Ratings Changes

Several equities research analysts have commented on KYTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Kyverna Therapeutics in a report on Thursday, April 23rd. Finally, Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Kyverna Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $28.67.

Institutional Investors Weigh In On Kyverna Therapeutics

Hedge funds have recently modified their holdings of the company. Empowered Funds LLC purchased a new stake in shares of Kyverna Therapeutics during the 4th quarter worth about $169,000. AQR Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics during the 1st quarter worth about $137,000. Federated Hermes Inc. boosted its stake in shares of Kyverna Therapeutics by 22.2% during the 2nd quarter. Federated Hermes Inc. now owns 44,000 shares of the company’s stock worth $135,000 after acquiring an additional 8,000 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Kyverna Therapeutics by 31.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock worth $132,000 after acquiring an additional 16,267 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Kyverna Therapeutics during the 2nd quarter worth about $107,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.